Results for HLD-0915 Demonstrate Encouraging Safety and Anti-Tumor Activity in Metastatic CRPC
“These preliminary results suggest that HLD-0915, an oral, once daily therapy, can achieve meaningful anti-tumor activity with a clean safety profile in mCRPC patients who had failed up to 8 prior mCRPC therapies,” said Dr. Andrew Hahn, Assistant Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, who presented the HLD-0915 data in the oral plenary session. “Furthermore, HLD-0915 demonstrated clinical activity regardless of genomic heterogeneity – including androgen receptor (AR) mutations, splice variants or amplifications. Given the limited treatment options for mCRPC patients, these clinical findings support the differentiated approach to drive a precision cell-killing effect through a novel mechanism that does not rely on cancer drivers that can cause drug resistance.”
Share:
More News
“FDA clearance of the IND for ORM-1153 is an important milestone for Orum, bringing another first-in-class DAC into the clinic and extending our approach into CD123-expressing hematologic malignancies,” said Olaf Christensen, M.D., Chief Medical Officer of Orum Therapeutics. “By combining cell-selective delivery with targeted protein degradation in a single molecule,
“We are excited to expand our clinical collaboration with Roche to evaluate a second KRAS combination with potential best-in-class MTA-cooperative PRMT5 inhibitor IDE892 for pancreatic cancer patients, where there remains a high unmet medical need. IDEAYA is advancing multiple rational combination strategies for the IDE892 program, including with MAT2A inhibitor
“These encouraging initial safety observations represent an important first step in the clinical evaluation of ZI-MA4-1 and our TCR-NK platform” said Namir Hassan, Chief Executive Officer of Zelluna. “The first patient received all three planned doses, and the independent committee’s recommendation enables us to continue recruitment at the first dose
“Receiving FTD is an important milestone for ERAS-0015 and reflects the urgent need for new therapies for patients with metastatic pancreatic cancer,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Together with the encouraging clinical activity and favorable tolerability observed to date, this FTD helps to position us